Mitozolomide

From WikiMD's WELLNESSPEDIA

Mitozolomide
Mitozolomide.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number 85622-95-3
PubChem 71766
DrugBank
ChemSpider 64805
KEGG

Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.

Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.[1] Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.[2]

References[edit]

  1. "Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide".Cancer Gene Ther.February 2000;7(2)
    233–9.doi:10.1038/sj.cgt.7700120.PMID:10770631.Full text.
  2. "Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)".Br J Cancer.February 1992;65(2)
    287–91.doi:10.1038/bjc.1992.57.PMID:1739631.PMC:1977719.